Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Kurze integrative und neurokognitive Therapie für junge Erwachsene mit Borderline-Persönlichkeitsstörung (SINTYA)

10. November 2026 aktualisiert von: Centre Hospitalier Universitaire de Nīmes

Kurze integrative und neurokognitive Therapie für junge Erwachsene mit Borderline-Persönlichkeitsstörung: ein Studienmodell zum Impulsivitätsmanagement

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

74

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre bis 25 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
  • High BPD severity level: ZAN-BPD (score ≥ 18/36).
  • Understand, write and read French.
  • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
  • Have signed the informed consent.
  • For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion Criteria:

  • Refusal to participate.
  • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
  • Intelligence quotient < 70.
  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
  • Previous or current participation in specific psychotherapy for BPD.
  • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
  • Inclusion in another study including psychotherapy for the duration of the study.
  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
  • Subject in period of exclusion from another research protocol.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Kontrolle
Experimental: SINTYA-Gruppe

10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Variation in explicit impulsivity between groups
Zeitfenster: Baseline

UPPS-S (Impulsive Behavior Scale Short version score)

Baseline
Variation in explicit impulsivity between groups
Zeitfenster: Month 4

UPPS-S (Impulsive Behavior Scale Short version score)

Month 4

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Variation in explicit impulsivity between groups
Zeitfenster: Month 7

UPPS-S (Impulsive Behavior Scale Short version score)

Month 7
Variation in impulsiveness between groups
Zeitfenster: Baseline

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Baseline
Variation in impulsiveness between groups
Zeitfenster: Month 4

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 4
Variation in impulsiveness between groups
Zeitfenster: Month 7

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 7
BPD severity level between groups
Zeitfenster: Baseline

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Baseline
BPD severity level between groups
Zeitfenster: Month 4

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 4
BPD severity level between groups
Zeitfenster: Month 7

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 7
Emotional regulation capacities between groups
Zeitfenster: Baseline

Difficulties in Emotion Regulation Scale (DERS-18)

Baseline
Emotional regulation capacities between groups
Zeitfenster: Month 4

Difficulties in Emotion Regulation Scale (DERS-18)

Month 4
Emotional regulation capacities between groups
Zeitfenster: Month 7

Difficulties in Emotion Regulation Scale (DERS-18)

Month 7
Dissociative symptoms between groups
Zeitfenster: Baseline

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Baseline
Dissociative symptoms between groups
Zeitfenster: Month 4

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 4
Dissociative symptoms between groups
Zeitfenster: Month 7

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 7
Aggression between groups
Zeitfenster: Baseline

Aggression Questionnaire (AQ-12)

Baseline
Aggression between groups
Zeitfenster: Month 4

Aggression Questionnaire (AQ-12)

Month 4
Aggression between groups
Zeitfenster: Month 7

Aggression Questionnaire (AQ-12)

Month 7
Ruminations between groups
Zeitfenster: Baseline

Rumination Reflection Questionnaire (RRQ)

Baseline
Ruminations between groups
Zeitfenster: Month 4

Rumination Reflection Questionnaire (RRQ)

Month 4
Ruminations between groups
Zeitfenster: Month 7

Rumination Reflection Questionnaire (RRQ)

Month 7
Number of self-destructive behaviors between groups
Zeitfenster: Baseline

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Baseline
Number of self-destructive behaviors between groups
Zeitfenster: Month 4

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 4
Number of self-destructive behaviors between groups
Zeitfenster: Month 7

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 7
Number of impulsive behaviors between groups
Zeitfenster: Baseline

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Baseline
Number of impulsive behaviors between groups
Zeitfenster: Month 4

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 4
Number of impulsive behaviors between groups
Zeitfenster: Month 7

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 7
Level of suicide risk between groups
Zeitfenster: Baseline

Columbia-Suicide Severity Rating Scale (C-SSRS)

Baseline
Level of suicide risk between groups
Zeitfenster: Month 4

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 4
Level of suicide risk between groups
Zeitfenster: Month 7

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 7
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Zeitfenster: 12 Months prior to inclusion

Information taken from patient medical file

12 Months prior to inclusion
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Zeitfenster: Baseline

Information taken from patient medical file

Baseline
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Zeitfenster: Month 4

Information taken from patient medical file

Month 4
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Zeitfenster: Month 7

Information taken from patient medical file

Month 7
Psychosocial functioning between groups
Zeitfenster: Baseline

Functional Assessment Staging Tool (FAST)

Baseline
Psychosocial functioning between groups
Zeitfenster: Month 4

Functional Assessment Staging Tool (FAST)

Month 4
Psychosocial functioning between groups
Zeitfenster: Month 7

Functional Assessment Staging Tool (FAST)

Month 7
Implicit impulsivity between groups
Zeitfenster: Baseline

Continuous Performance Test (CPT)

Baseline
Implicit impulsivity between groups
Zeitfenster: Month 4

Continuous Performance Test (CPT)

Month 4
Implicit impulsivity between groups
Zeitfenster: Month 7

Continuous Performance Test (CPT)

Month 7
Neurocognitive evaluation of implicit impulsivity between groups
Zeitfenster: Baseline

Emotional Stroop (SE) customized to the study

Baseline
Neurocognitive evaluation of implicit impulsivity between groups
Zeitfenster: Month 4

Emotional Stroop (SE) customized to the study

Month 4
Neurocognitive evaluation of implicit impulsivity between groups
Zeitfenster: Month 7

Emotional Stroop (SE) customized to the study

Month 7
Risk taking between groups
Zeitfenster: Baseline

Balloon Analogue Risk Task (BART)

Baseline
Risk taking between groups
Zeitfenster: Month 4

Balloon Analogue Risk Task (BART)

Month 4
Risk taking between groups
Zeitfenster: Month 7

Balloon Analogue Risk Task (BART)

Month 7
Decision making under risk conditions between groups
Zeitfenster: Baseline

Game Dice Task (GDT)

Baseline
Decision making under risk conditions between groups
Zeitfenster: Month 4

Game Dice Task (GDT)

Month 4
Decision making under risk conditions between groups
Zeitfenster: Month 7

Game Dice Task (GDT)

Month 7

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Clémentine Estric, CHU de Nimes

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. November 2023

Primärer Abschluss (Tatsächlich)

13. September 2025

Studienabschluss (Tatsächlich)

22. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

22. Mai 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Juni 2023

Zuerst gepostet (Tatsächlich)

22. Juni 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NIMAO/2022-1/CE-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All IPD that underlie results in a publication

IPD-Sharing-Zeitrahmen

Upon publication

IPD-Sharing-Zugriffskriterien

The IPD will be made available to other researchers upon reasonable request to the corresponding author

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • ANALYTIC_CODE

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .